BlueWhale Bio
BlueWhale Bio is committed to advancing cell-based therapeutics through manufacturing innovation.
BlueWhale Bio is committed to advancing cell-based therapeutics through manufacturing innovation.
BlueWhale Bio has raised $10.0M across 2 rounds. Its most recent round was a Venture - Series Unknown of $5.0M in Oct 2025. Full funding history, investors, and team are detailed below.
Funding history
2 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
BlueWhale Bio is featured in
Similar companies
Rion Vet mission is to drive the regenerative medicine revolution.
Modulight Bio develops an optogenetic platform intended for the treatment of neurological disorders.
Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative diseases.
Gregor Diagnostics is a molecular diagnostics company developing a screening test technology for prostate cancer.
Gut Brain Axis Therapeutics is a biotechnology company that offers treatment for Autism Spectrum Disorder with microbial transplant therapy.
iOrganBio is a pioneering cell production platform.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
NILO Therapeutics is a biotechnology and therapeutics company.
Predicta Biosciences provides molecular diagnostics and immunotherapeutic discovery services for hematological diseases.
AccufyDx is a Biotechnology Research firm working to change MRD analysis for early detection.Accufy Diagnostics, Inc.
Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients.
Reprogenix is a groundbreaking medical technology firm
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.